These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 28652196)

  • 1. Efficacy of Escherichia coli-derived recombinant human bone morphogenetic protein-2 in posterolateral lumbar fusion: an open, active-controlled, randomized, multicenter trial.
    Cho JH; Lee JH; Yeom JS; Chang BS; Yang JJ; Koo KH; Hwang CJ; Lee KB; Kim HJ; Lee CK; Kim H; Suk KS; Nam WD; Han J
    Spine J; 2017 Dec; 17(12):1866-1874. PubMed ID: 28652196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mid-term efficacy and safety of Escherichia coli-derived rhBMP-2/hydroxyapatite carrier in lumbar posterolateral fusion: a randomized, multicenter study.
    Cho M; You KH; Yeom JS; Kim H; Lee KB; Cho JH; Yang JJ; Lee JH
    Eur Spine J; 2023 Jan; 32(1):353-360. PubMed ID: 36394652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Posterolateral lumbar fusion using Escherichia coli-derived rhBMP-2/hydroxyapatite in the mini pig.
    Kong CB; Lee JH; Baek HR; Lee CK; Chang BS
    Spine J; 2014 Dec; 14(12):2959-67. PubMed ID: 24937799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The safety and efficacy of OP-1 (rhBMP-7) as a replacement for iliac crest autograft for posterolateral lumbar arthrodesis: minimum 4-year follow-up of a pilot study.
    Vaccaro AR; Whang PG; Patel T; Phillips FM; Anderson DG; Albert TJ; Hilibrand AS; Brower RS; Kurd MF; Appannagari A; Patel M; Fischgrund JS
    Spine J; 2008; 8(3):457-65. PubMed ID: 17588821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: a prospective, randomized clinical pilot trial: 2002 Volvo Award in clinical studies.
    Boden SD; Kang J; Sandhu H; Heller JG
    Spine (Phila Pa 1976); 2002 Dec; 27(23):2662-73. PubMed ID: 12461392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of Escherichia coli-derived recombinant human bone morphogenetic protein-2 in additional lumbar posterolateral fusion: minimum 1-year follow-up.
    Son HJ; Choi SH; Lee MK; Kang CN
    Spine J; 2021 Aug; 21(8):1340-1346. PubMed ID: 33848691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is lumbar facet fusion biomechanically equivalent to lumbar posterolateral onlay fusion?
    Toth JM; Foley KT; Wang M; Seim HB; Simon Turner A
    J Neurosurg Spine; 2017 May; 26(5):586-593. PubMed ID: 28156207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Posterior lumbar interbody fusion using recombinant human bone morphogenetic protein type 2 with cylindrical interbody cages.
    Haid RW; Branch CL; Alexander JT; Burkus JK
    Spine J; 2004; 4(5):527-38; discussion 538-9. PubMed ID: 15363423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone morphogenetic protein-2 and bone marrow aspirate with allograft as alternatives to autograft in instrumented revision posterolateral lumbar spinal fusion: a minimum two-year follow-up study.
    Taghavi CE; Lee KB; Keorochana G; Tzeng ST; Yoo JH; Wang JC
    Spine (Phila Pa 1976); 2010 May; 35(11):1144-50. PubMed ID: 20139805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and radiographic analysis of an optimized rhBMP-2 formulation as an autograft replacement in posterolateral lumbar spine arthrodesis.
    Dimar JR; Glassman SD; Burkus JK; Pryor PW; Hardacker JW; Carreon LY
    J Bone Joint Surg Am; 2009 Jun; 91(6):1377-86. PubMed ID: 19487515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pilot study evaluating the safety and efficacy of OP-1 Putty (rhBMP-7) as a replacement for iliac crest autograft in posterolateral lumbar arthrodesis for degenerative spondylolisthesis.
    Vaccaro AR; Patel T; Fischgrund J; Anderson DG; Truumees E; Herkowitz HN; Phillips F; Hilibrand A; Albert TJ; Wetzel T; McCulloch JA
    Spine (Phila Pa 1976); 2004 Sep; 29(17):1885-92. PubMed ID: 15534410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes and fusion success at 2 years of single-level instrumented posterolateral fusions with recombinant human bone morphogenetic protein-2/compression resistant matrix versus iliac crest bone graft.
    Dimar JR; Glassman SD; Burkus KJ; Carreon LY
    Spine (Phila Pa 1976); 2006 Oct; 31(22):2534-9; discussion 2540. PubMed ID: 17047540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the efficacy and safety of Escherichia coli-derived recombinant human bone morphogenetic protein-2 in transforaminal lumbar interbody fusion to treat degenerative spinal disease: a protocol of prospective, randomized controlled, assessor-blinded, open-label, multicenter trial.
    Choi JY; Park HJ; Park SM; Kang CN; Song KS
    J Orthop Surg Res; 2022 Aug; 17(1):397. PubMed ID: 36045371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lumbar spinal fusion with β-TCP granules and variable Escherichia coli-derived rhBMP-2 dose.
    Pelletier MH; Oliver RA; Christou C; Yu Y; Bertollo N; Irie H; Walsh WR
    Spine J; 2014 Aug; 14(8):1758-68. PubMed ID: 24486479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes and fusion rates following anterior lumbar interbody fusion with bone graft substitute i-FACTOR, an anorganic bone matrix/P-15 composite.
    Mobbs RJ; Maharaj M; Rao PJ
    J Neurosurg Spine; 2014 Dec; 21(6):867-76. PubMed ID: 25325176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fusion rate of Escherichia coli-derived recombinant human bone morphogenetic protein-2 compared with local bone autograft in posterior lumbar interbody fusion for degenerative lumbar disorders.
    Park S; Jeong YH; Ha BJ; Yoo BS; Kim SH; Lee CK; Yi S; Ha Y; Kim KN; Shin DA
    Spine J; 2023 Dec; 23(12):1877-1885. PubMed ID: 37516282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and Feasibility of Injectable Escherichia coli-Derived Recombinant Human Bone Morphogenetic Protein-2 for Anterior Lumbar Interbody Fusion at the Lumbosacral Junction in Adult Spinal Deformity Surgery: A Clinical Pilot Study.
    Im SK; Lee JH; Lee KY; Yoo SJ
    Orthop Surg; 2022 Jul; 14(7):1350-1358. PubMed ID: 35633034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two-year fusion and clinical outcomes in 224 patients treated with a single-level instrumented posterolateral fusion with iliac crest bone graft.
    Dimar JR; Glassman SD; Burkus JK; Pryor PW; Hardacker JW; Carreon LY
    Spine J; 2009 Nov; 9(11):880-5. PubMed ID: 19447682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Prospective, Randomized, Multicenter Study Comparing Silicated Calcium Phosphate versus BMP-2 Synthetic Bone Graft in Posterolateral Instrumented Lumbar Fusion for Degenerative Spinal Disorders.
    Coughlan M; Davies M; Mostert AK; Nanda D; Willems PC; Rosenberg G; Ferch R
    Spine (Phila Pa 1976); 2018 Aug; 43(15):E860-E868. PubMed ID: 29652784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of radiographic and clinical outcomes of anterior lumbar interbody fusion performed with either a cellular bone allograft containing multipotent adult progenitor cells or recombinant human bone morphogenetic protein-2.
    Lee DD; Kim JY
    J Orthop Surg Res; 2017 Aug; 12(1):126. PubMed ID: 28841904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.